Eric W. Roberts - 05 Feb 2024 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Role: CHIEF BUSINESS OFFICER, Director, 10%+ Owner
Signature: /s/ John Dunn, Attorney-in-Fact
Issuer symbol: CALC
Transactions as of: 05 Feb 2024
Net transactions value: +$400,004
Form type: 4
Filing time: 06 Feb 2024, 17:34:17 UTC
Previous filing: 08 Nov 2023
Next filing: 22 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CALC	Common Stock	Award	$388,618	+91,086	+449%	$4.27	111,373	05 Feb 2024	Direct	F1
holding	CALC	Common Stock						35,894	05 Feb 2024	By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA
holding	CALC	Common Stock						5,223	05 Feb 2024	By FMTC Custodian - Roth IRA FBO Eric W. Roberts
holding	CALC	Common Stock						10,661	05 Feb 2024	By IRA Financial Trust Company CFBO Eric W. Roberts
holding	CALC	Common Stock						356,989	05 Feb 2024	By Valence Investments SPV IV, LLC	F2
holding	CALC	Common Stock						66,228	05 Feb 2024	By Valence Investments SPV V, LLC	F2
holding	CALC	Common Stock						316,109	05 Feb 2024	By Valence Investments SPV VI, LLC	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CALC	Warrant	Award	$5,693	+45,543		$0.1250^*	45,543	05 Feb 2024	Common Stock	45,543	$5.36	Direct	F1, F3
transaction	CALC	Warrant	Award	$5,693	+45,543		$0.1250^*	45,543	05 Feb 2024	Common Stock	45,543	$7.15	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of February 5, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
F2	The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of his pecuniary interest therein.
F3	The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
F4	The warrant may be exercised on or after February 5, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.